We are turning 10!
Join us for a reception on November 30 at the Grand Concourse to see how far we've come with your support ... and just how far we plan to go.
Virtual by Zoom Presented by Dr. Yasaswi Kislovskiy AHN Register online here! *** Industry partners must have an exhibit or sponsorship to participate in the Community Liver Alliance programs […]
PBC Update Virtual Program for Patients & Caregivers October 16, 2023 6:00-8:00 p.m. EST Expert speaker: Alex Myint, MD Transplant Hepatology, UPMC Center for Liver Diseases The interactive program includes […]
Presented by Alisha Davis, MD Duke Health Virtual via Zoom - Register now!
Annual Liver Cancer Conference October 28, 2023 8:15 a.m. – 3:00 p.m. ET Virtual & Free Event! Click here to register! *Industry partners must have an exhibit or sponsorship to participate […]
Hosted by Matthew Barnes, CRNP Crossroads Treatment Center Virtual via Zoom - Register now! *** Industry partners must have an exhibit or sponsorship to participate in the Community […]
Opportunities to discuss what is new in the Hep C space with other professionals. Each meeting we will focus on one particular organization and their work, with a collaborative discussion […]
News & Information
News & Information
There is 80 to 100 million people in the USA that have Fatty Liver Disease and most do not even know they have it. Liver Disease does not discriminate. It affects any age, social economics and race. Liver cancer incidence rates have more than tripled since 1980, while the death rates have more than doubled during this time.
Ensure funding for COVID-19 and liver disease public health programs, research, vaccine dissemination; ensure that people living with liver disease are not disproportionately impacted and do not experience unnecessary or discriminatory health care or treatment disruptions.
Address inequities in the care of people impacted by liver disease, especially the excess incidence rate of liver cancer in black men in America.
Advance the U.S. NASH Action Plan, and ensure patients with liver disease perspectives are represented in relevant legislative packages: COVID-19, diabetes, and obesity.
Work with regulators to establish logical pathways to consistently approve therapies for liver diseases, particularly rare liver diseases.
Advocate for funding that ensures meaningful growth of vital liver disease research and the improving of liver health.
Urgently respond to the inequities that impact organ transplantation; modernize the U.S. Organ Donation system, improve care for transplant patients, and increase the number of available organs.
Increase support for hepatitis programs and raise awareness of viral hepatitis; advocate for the elimination of viral hepatitis .
Advance health care policies that reflect each person’s unique needs and drive access to personalized, patient-centric care.
Support policy solutions that curb patients’ health care expenses; advocate for the smoothing and capping of out-of-pocket costs in Medicare Part D.